Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts

China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. US lawmakers and officials at the Food and Drug Administration (